How do synthetic EVs achieve brain-specific targeting while avoiding reticuloendothelial clearance?
PARTIALLY ADDRESSED
All participants identified brain delivery as a critical barrier, but no mechanism was proposed for overcoming BBB limitations or avoiding systemic clearance. This represents a fundamental delivery challenge for all EV-based CNS therapeutics.
Source: Debate session sess_SDA-2026-04-02-gap-ev-ad-biomarkers (Analysis: SDA-2026-04-02-gap-ev-ad-biomarkers)
Priority: 0.88Domain: drug-deliveryHypotheses: 0
📊 Landscape Analysis
Landscape Summary:
How do synthetic EVs achieve brain-specific targeting while avoiding reticuloendothelial clearance? is a 0.88 priority gap in drug-delivery.
It has 0 linked hypotheses with average composite score 0.000.
Status: partially_addressed.
Key Unanswered Questions
What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?
Key Researchers
Colonna, Sevlever, et al. (TREM2 biology)
Clinical Trials
How do synthetic EVs achieve brain-specific targeting while avoiding reticuloendothelial clearance? — INVOKE-2 (completed)